More than half of neurology trial sites now take longer than five months to activate, according to a June 2025 survey of over 100 principal investigators and senior site staff. At $55,716 in direct costs per day for a Phase III program, five months of activation delay is roughly $8.5 million in operational exposure, and that figure assumes enrollment recovers cleanly once the site opens. It does not.
The recovery problem is the real story. CNS sites begin building pre-screening pipelines two to three months before their expected activation date, drawing from patient registries to have candidates ready the moment they can enroll. When activation slips from month four to month seven, those candidates have moved on: disease has progressed past eligibility windows, patients have declined after waiting, or a competing trial has enrolled them. Sponsors who respond by adding replacement sites face the same five-month runway at each new location, with no existing patient pipeline. The enrollment curve does not bounce back; it resets.
The survey data explains why. Budget negotiations are the most commonly cited barrier, named by 72% of sites, with contract finalization cited by 60%. Nearly half of sites rate sponsor and CRO communication as average or poor. Meanwhile, the CNS-specific prerequisites that distinguish neurology programs from other therapeutic areas, rater certification for scales like ADAS-Cog, CDR, and MDS-UPDRS; PET or CSF biomarker infrastructure qualification; caregiver and legally authorized representative consent workflow approval, are typically initiated at or after the site initiation visit in reactive programs, meaning a site can be marked “active” on paper while still weeks away from enrolling anyone. The industry target for end-to-end site startup is 90 to 120 days; ACRP’s 2025 data puts the actual median at academic medical centers between 140 and 167 days, with some sites exceeding 300 days when contract negotiations stall.
For a program running 80 to 100 global sites, the gap between a 90-day median and a 167-day median is not a scheduling footnote. It is the difference between hitting first-patient-in on budget and opening a Phase III readout meeting with an explanation for why enrollment is already six months behind. The metric to watch is not activation rate but rater certification completion relative to the site initiation visit date: if credentialing finishes after the SIV, the site’s activation date is fiction.
Source link: https://sitero.com/site-activation-in-neurology-trials-the-real-cost-of-delay/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
